Tambocor and Gastrointestinal inflammation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal inflammation is reported only by a few people who take Tambocor.

The phase IV clinical study analyzes which people take Tambocor and have Gastrointestinal inflammation. It is created by eHealthMe based on reports of 2,316 people who have side effects while taking Tambocor from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 16, 2022

2,316 people reported to have side effects when taking Tambocor.
Among them, 3 people (0.13%) have Gastrointestinal inflammation.


What is Tambocor?

Tambocor has active ingredients of flecainide acetate. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 2,421 Tambocor users for its effectiveness, alternative drugs and more.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 772 drugs and 511 conditions by eHealthMe.

Number of Tambocor and Gastrointestinal inflammation reports submitted per year:

Could Tambocor cause Gastrointestinal inflammation?

Gender of people who have Gastrointestinal inflammation when taking Tambocor *:

  • female: 0.0 %
  • male: 100 %

Age of people who have Gastrointestinal inflammation when taking Tambocor *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 100 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Common drugs people take besides Tambocor *:

  1. Norditropin: 1 person, 33.33%
  2. Leuprolide Acetate: 1 person, 33.33%
  3. Enalapril Maleate: 1 person, 33.33%
  4. Digoxin: 1 person, 33.33%

Common side effects people have besides Gastrointestinal inflammation *:

  1. Venous Pressure Increased: 3 people, 100.00%
  2. Protein-Losing Gastroenteropathy (gastrointestinal tract that results in a net loss of protein from the body): 3 people, 100.00%
  3. Gastrointestinal Oedema (excessive build-up of fluid in the gastrointestinal tract tissues): 3 people, 100.00%
  4. Gastritis Atrophic (process of chronic inflammation of the stomach mucosa): 3 people, 100.00%
  5. Diarrhea: 2 people, 66.67%

Common conditions people have *:

  1. Precocious Puberty: 3 people, 100.00%
  2. Growth Hormone Deficiency: 3 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tambocor and have Gastrointestinal inflammation?

Check whether Gastrointestinal inflammation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

How severe was Gastrointestinal inflammation and when was it recovered:

Expand to all the drugs that have ingredients of flecainide acetate:

Alternative drugs to, pros and cons of Tambocor:

Common Tambocor side effects:

Browse all side effects of Tambocor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Gastrointestinal inflammation treatments and more:

COVID vaccines that are related to Gastrointestinal inflammation:

Common drugs associated with Gastrointestinal inflammation:

All the drugs that are associated with Gastrointestinal inflammation:

Common conditions associated with Gastrointestinal inflammation:

All the conditions that are associated with Gastrointestinal inflammation:

How the study uses the data?

The study uses data from the FDA. It is based on flecainide acetate (the active ingredients of Tambocor) and Tambocor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: